On 5th June, a portfolio of shares in 19 life science companies was agreed to be sold by Neil Woodford’s LF Equity Income Fund to Acacia Research for up to £224 million. To date, nine assets have been transferred to Acacia Research, many of these have already been sold on.
Acacia acquires Biotech Stakes looks at the patent assets and companies behind the deal and delves into:
Find out in our latest article which companies and patents are involved in this deal as well as what this says about Acacia’s strategy.
Ensure you have the right portfolio to meet your strategic patenting objectives.
Understand who’s doing what by automating patent to technology mapping.
Combine patent and revenue data to determine rational licensing outcomes.
Justify patent budgets and communicate the impact of your investment.
Automate manual reviews for efficient execution of M&A and licensing transactions.
Be prepared with evidence to create a fast and effective threat assessment.
Assess your portfolio in comparison to other owners through your technology lens.
Identify opportunities to create value through licensing or sale of patent assets.
Track new technologies and discover the unknown owners of future innovation.
Understand the materiality of your threats to define your risk mitigation strategy.
Speak to our team today.
